Osimertinib
Osimertinib (AZD-9291) is an oral, irreversible third-generation EGFR inhibitor designed to target the T790M resistance mutation in non-small cell lung cancer (NSCLC) . It is widely used in preclinical research, demonstrating potent antitumor activity in both in vitro cell assays and in vivo xenograft models of EGFR-mutant NSCLC.
Product Specifications
CAS Number
1421373-65-0
Product Name Alternative
AZD-9291
Field of Research
Cardiovascular Research, Pharmacology & Drug Discovery, Signal Transduction
Purity
>98%
Form
Powder
Solubility
Soluble in DMSO (up to 40 mg/ml)
Smiles
CN1C=C (C=2C1=CC=CC2) C3=NC (NC4=C (OC) C=C (N (CCN (C) C) C) C (NC (C=C) =O) =C4) =NC=C3
Molecular Formula
C28H33N7O2
Molecular Weight
499.6
Storage Conditions
-20°C
Notes
For research use only.
Other Product Names
N-[2-[[2- (Dimethylamino) ethyl]methylamino]-4-methoxy-5-[[4- (1-methyl-1H-indol-3-yl) -2-pyrimidinyl]amino]phenyl]-2-propenamide
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Recombinant Human RAD51-associated protein 2 (R51A2), partial
Recombinant Human RAD51-associated protein 2 (R51A2), partial
Recombinant Human RAD51-associated protein 2 (R51A2), partial
